During the past decade, Hôpital Claude Huriez conducted 309 clinical trials. In the 10-year time frame, 309 clinical trials started and 80 clinical trials were completed, i.e. on average, 25.9% percent of trials that started reached the finish line to date. In the past 5 years, 142 clinical trials started and 51 clinical trials were completed. i.e. 35.9% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hôpital Claude Huriez" #1 sponsor was "University Hospital, Lille" with 101 trials, followed by "The Lymphoma Academic Research Organisation" with 27 trials sponsored, "Celgene" with 24 trials sponsored, "Hoffmann-La Roche" with 15 trials sponsored and "Janssen Research & Development, LLC" with 15 trials sponsored. Other sponsors include 304 different institutions and companies that sponsored additional 149 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hôpital Claude Huriez" #1 collaborator was "Ministry of Health, France" with 19 trials as a collaborator, "Roche Pharma AG" with 8 trials as a collaborator, "Sanofi" with 7 trials as a collaborator, "AbbVie" with 6 trials as a collaborator and "Bristol-Myers Squibb" with 6 trials as a collaborator. Other collaborators include 183 different institutions and companies that were collaborators in the rest 142 trials.

According to Clinical.Site data, the most researched conditions in "Hôpital Claude Huriez" are "Multiple Myeloma" (38 trials), "Ulcerative Colitis" (17 trials), "Crohn Disease" (11 trials), "Crohn's Disease" (11 trials) and "Lymphoma, Non-Hodgkin" (10 trials). Many other conditions were trialed in "Hôpital Claude Huriez" in a lesser frequency.

Most popular intervention types in "Hôpital Claude Huriez" are "Drug" (318 trials), "Other" (60 trials), "Procedure" (40 trials), "Biological" (31 trials) and "Device" (24 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (61 trials), "Rituximab" (23 trials), "Dexamethasone" (22 trials), "Lenalidomide" (19 trials) and "Obinutuzumab" (11 trials). Other intervention names were less common.

The vast majority of trials in "Hôpital Claude Huriez" are 467 trials for "All" genders, 16 trials for "Male" genders and 7 trials for "Female" genders.

Currently, there are NaN active trials in "Hôpital Claude Huriez". 3 are not yet recruiting, 116 are recruiting, 61 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 232 completed trials in Hôpital Claude Huriez, 1 suspended trials, and 45 terminated clinical trials to date.

Out of the total trials that were conducted in Hôpital Claude Huriez, 46 "Phase 1" clinical trials were conducted, 161 "Phase 2" clinical trials and 151 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 10 trials, and there were also 63 trials that are defined as “Not Applicable".